Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) – Stock analysts at Leerink Swann issued their FY2022 earnings per share estimates for shares of Jazz Pharmaceuticals in a research report issued on Tuesday. Leerink Swann analyst A. Fadia forecasts that the specialty pharmaceutical company will post earnings per share of $21.94 for the year. Leerink Swann currently has a “Outperform” rating and a $180.00 price objective on the stock.

Several other research analysts have also issued reports on JAZZ. Royal Bank of Canada reiterated a “buy” rating and issued a $210.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, September 15th. UBS Group reiterated a “buy” rating and issued a $172.00 price target (down from $175.00) on shares of Jazz Pharmaceuticals in a research note on Monday, September 25th. Wells Fargo & Co reissued an “outperform” rating and set a $172.00 price objective (down from $177.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, November 8th. BMO Capital Markets reissued a “buy” rating and set a $196.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, September 20th. Finally, Zacks Investment Research downgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and nineteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $181.68.

Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) opened at $135.59 on Friday. The company has a current ratio of 3.10, a quick ratio of 2.94 and a debt-to-equity ratio of 0.63. Jazz Pharmaceuticals has a 1-year low of $112.52 and a 1-year high of $163.75. The company has a market cap of $8,197.63, a price-to-earnings ratio of 17.16, a P/E/G ratio of 0.74 and a beta of 0.98.

In related news, Director Patrick G. Enright sold 352 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $133.19, for a total value of $46,882.88. Following the sale, the director now owns 1,365 shares in the company, valued at $181,804.35. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Michael Patrick Miller sold 200 shares of the company’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $139.15, for a total value of $27,830.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,552 shares of company stock worth $2,399,643. 4.30% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Toronto Dominion Bank boosted its position in Jazz Pharmaceuticals by 12.4% in the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after buying an additional 81 shares during the last quarter. Advisor Group Inc. boosted its position in Jazz Pharmaceuticals by 62.4% in the 3rd quarter. Advisor Group Inc. now owns 1,431 shares of the specialty pharmaceutical company’s stock worth $210,000 after purchasing an additional 550 shares in the last quarter. SG Americas Securities LLC boosted its position in Jazz Pharmaceuticals by 13.0% in the 2nd quarter. SG Americas Securities LLC now owns 1,384 shares of the specialty pharmaceutical company’s stock worth $215,000 after purchasing an additional 159 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new stake in Jazz Pharmaceuticals in the 2nd quarter worth approximately $227,000. Finally, Intl Fcstone Inc. purchased a new stake in Jazz Pharmaceuticals in the 2nd quarter worth approximately $230,000. Hedge funds and other institutional investors own 90.73% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was published by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/leerink-swann-comments-on-jazz-pharmaceuticals-plc-s-fy2022-earnings-jazz/1797269.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.